[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"beta-lactam-antibiotics\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:beta-lactam-antibiotics":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100572861","antimicrobial-therapy-for-difficult-to-treat-pseudomonas-aeruginosa-100572861",false,"NCT06738771","Antimicrobial Therapy for Difficult-to-treat Pseudomonas Aeruginosa","Antimicrobial Therapy for Infections Due to Pseudomonas Aeruginosa With Difficult-to-treat Resistance: a Real-world, Prospective, Multicenter Cohort Study","ADDICT","Inclusion Criteria:\n\n* All patients aged 18 or over and requiring intravenous definite antimicrobial therapy for a DTR P. aeruginosa infection\n\nExclusion Criteria:\n\n* Cystic fibrosis\n* P. aeruginosa DTR colonization or P. aeruginosa DTR infection not requiring definitive intravenous antibiotic therapy\n* Protected person (under guardianship or curatorship)\n* Persons under court protection\n* Persons deprived of liberty\n* Opposition expressed for participation in the study","ALL","18 Years",{"count":20,"type":21},600,"ESTIMATED","OBSERVATIONAL","The primary objective of the ADDICT study is to assess and compare the clinical efficacy of available options for antimicrobial therapy (new beta-lactam\u002Fbeta-lactamase inhibitor combination, cefiderocol or older agents such as aminoglycosides and colistin) in unselected patients with infection due to difficult-to-treat P. aeruginosa.",[25,26,27,28,29,30],"Pseudomonas Infections","Pseudomonas Aeruginosa","Prognosis","Drug Resistance, Multiple, Bacterial","Antibacterial Agents","Beta-lactam Antibiotics","RECRUITING","2026-04-29",{"date":34,"type":35},"2026-04-30","ACTUAL",{"date":37,"type":35},"2025-03-11",{"date":39,"type":21},"2027-01",{"name":41,"class":42},"Centre Hospitalier Régional d'Orléans","OTHER",48]